64 results about "HPMA polymer" patented technology

The invention provides a composite phosphorus-free corrosion and scale inhibitor and its application. The composite phosphorus-free corrosion and scale inhibitor is composed of a corrosion and scale inhibitor A and a corrosion and scale inhibitor B, wherein the corrosion and scale inhibitor A is obtained through mixing polyepoxysuccinic acid (PESA), sodium gluconate and water; and the corrosion and scale inhibitor B is obtained through mixing hydrolytic polymaleic anhydride (HPMA), an acrylic acid/2-acrylamide-2-methylpropanesulfonic acid copolymer (AA/AMPS), a zinc salt, a fluorescent tracer and water. The composite phosphorus-free corrosion and scale inhibitor, which compounds the corrosion and scale inhibitor A and the corrosion and scale inhibitor B according to a weight ratio of the corrosion and scale inhibitor A to the corrosion and scale inhibitor B of 1:2, has the advantages of excellent corrosion and scale inhibition effects, avoiding of a water eutrophication problem caused by phosphorus discharge, environmental pollution mitigation, and good environmental protection property.

The present invention provides bone-targeting polymeric drug delivery systems based on HPMA and related copolymers and methods of making thereof. The water-soluble bone-targeting polymeric conjugates of the present invention comprise water-soluble copolymer backbones (P) which are linked, via a first spacer (S₁), with a bone-related therapeutic agents or drug (D) and, via a second spacer (S₂), with a bone-targeting moiety (T).

The invention discloses a chromate-free passivation agent for an aluminum alloy. Per liter of chromate-free passivation agent is composed of, by mass, 10 mg to 300 mg of amino silane or/and epoxy silane, 1 mg-100 mg of dispersible nano particles, 10 mg-500 mg of a zirconium compound or/and a titanium compound, 1 mg-150 mg of metal ions, 10 mg-150 mg of fluoride, 1 mg-20 mg of a complexing agent, 75 mg-100 mg of organic phosphoric acid and the balance water; and the organic phosphoric acid is at least two of HEDP, HPMA, EDTMP, DTPMP, ATMP and PBTCA. According to the passivation agent, multiple kinds of organic phosphoric acid, multiple kinds of metal ions and multiple kinds of nano particles are chelated to the different degrees; on one aspect, the thickness and the compactness of a passivation film layer can be strengthened; and meanwhile, the passivation film layer (inorganic film layer) formed after chelation can show a color to a certain degree on the surface of the aluminum alloy.

The invention belongs to the field of a medicine slow release carrier material and specifically discloses a preparing method for slow release hydrogel carrier material with a semi-interpenetrating structure modified by a polyelectrolyte membrane and an application thereof. The slow release hydrogel material is comprised of HPMC and SA as raw materials, firstly an HPMC-SA semi-interpenetrating composite gel is prepared by a Ca2+ physical crosslinking method and polyelectrolyte membrane modification is performed on the HPMC-SA hydrogel with low molecular weight CS so as to increase the stabilityof the HPMA-SA hydrogel, so that the HPMA-SA-CS hydrogel is obtained. The hydrogel has advantages of mild preparing condition, simple method, less reagent and no violent reactions. BSA and micromolecule indissolvable IDM are regarded as model medicine and the slow release effect of the HMPC-SA-CS composite hydrogel material on macro-molecule medicine and micromolecule medicine is investigated. The result shows that the gel system continuously swell for 50 hours, the swellability reaches above 52 times and the slow release effect of the protein medicine and IDM is increased.

The invention discloses an N-(2-hydroxypropyl) methacrylamide polymer based nanoparticles capable of overcoming a mucus barrier and a preparation method thereof. The nanoparticles consist of nucleuses and shells, wherein the kernels are a nanometer compound prepared from a biocompatible carrier material and active ingredients, and the shells are an HPMA polymer and its derivatives.

The invention relates to a circulating water scale inhibitor, which comprises the following components by weight portion: 2. 5 to 2.8 portions of PASP (polyaspartic acid), 1 to 1.2 portions of ATMP (amino trimethylene phosphonic acid), 2.4 to 2.6 portions of HPMA (hydrolyzed polymaleic anhydride), 1.2 to 1.4 portions of AA/AMPS (acrylic acid and 2-acrylamide-2-methyl propane sulfonic acid copolymer), 1.1 to 1.3 portions of PAA (polyacrylic acid), and 0.7 to 1.8 portions of water. The scale inhibitor prepared by the formulation is environment-friendly, has the characteristics of safety and reliability, easy preparation, convenient use and the like, and is suitable to be used as medicaments for preventing scale on circulating water systems in the fields of electric power, chemical engineering, medicine, petroleum, and the like.

The invention provides a tumor microenvironment stimulation degradable amphiphilic block HPMA (hydroxypropyl methacrylate) polymer delivery system which is a conjugate of HPMA polymer, cathepsin B substrate GFLG, and small-molecular drug gemcitabine; the nano delivery system formed by self-assembly of the amphiphilic block conjugate has enzyme responsive degrading capacity and drug release capacity, gemcitabine is delivered by being conjugated to the amphiphilic block HPMA polymer skeleton, the molecular weight of the system is relatively high, the system may effectively collect at a tumor part, has good biocompatibility and antitumor effect, and by introducing near-infrared fluorescent probe Cy5.5, self-tracing capacity is imparted to the system.

The invention relates to a preparing method of a PDLC (polymer dispersed liquid crystal) dimming glass film. The method particularly comprises the following steps that in a light shading environment, resin, photoinitiators, HPMA (hydroxypropyl methacrylate), OPPEA (ortho-phenyl phenoxyl ethyl acrylate) and LMA (lauryl methacrylate) are proportionally mixed; after the mixing, the materials are uniformly stirred for about 30 minutes at the room temperature being about 25 DEG C; a mixture A is obtained; 35 percent of the mixture A is mixed with 65 percent of liquid crystals, and the mixture is uniformly stored for about 30 minutes at the room temperature about 25 DEG C; a mixture B is obtained; 0.5-percent 20um nanometer materials are added to be mixed with the mixture B, and the mixture is uniformly stirred for about 30 minutes at the room temperature being about 25 DEG C; finally, PDLC raw materials are obtained; coating and pressing are carried out; the curing process is carried out. The method provided by the invention includes the PDLC raw material preparation and a film production method. The production cost of the PDLC film is greatly reduced.

The invention discloses a novel efficient anti-tumor targeting drug carrier and a preparation method thereof. The carrier is a diblock copolymer consisting of a chain segment A and a chain segment B, wherein the chain segment A is PEG, and the chain segment B is a random copolymer formed by the following three monomers: HPMA, MAGG and BHMAGG. By adoption of a reversible addition fragmentation chain transfer polymerization method, the copolymer with controllable copolymerization components and molecular weight, and narrow molecular weight distribution (with the molecular weight distribution PDI being less than 1.4) is obtained. By modification of side chain functional groups of the MAGG and the BHMAGG in the polymer, a water-soluble polymer drug carrying system with significant targeting and controlled drug release functions is obtained. The polymer drug carrying system can be used for efficient transportation of anti-tumor drugs, has advantages of high targeting property, good biocompatibility, adjustable drug carrying amount, and drug release with pH responsiveness, and is an anti-tumor targeting drug carrier with excellent performances.

The invention discloses a PEG modified PHPMA material and a preparation method thereof. The PEG modified PHPMA material which is provided by the invention is N-(2'-hydroxyl) propyl methyl acrylamide (HPMA) and/or a copolymer of the derivative of the N-(2'-hydroxyl) propyl methyl acrylamide and polyethylene glycol (PEG). The PEG modified PHPMA material of the invention is a polymer which is formed by the copolymerization of the polyethylene glycol (PEG), poly-N-(2'-hydroxyl) propyl methyl acrylamide (PHPMA) and the derivative of the PHPMA, the copolymer can be obtained by adopting the reversible addition-fragmentation chain transfer (RAFT), the composition and the molecular weight are controllable, and the molecular weight distribution is narrow (the molecular weight distribution d is less than 1, 4). Such polymers can be applied in the targeting drug delivery, which can not only have high targeting property and good biocompatibility, but can also have the function of preventing the protein non-specific absorption after the PEG modification, so the PEG modified PHPMA material is a good drug targeting carrier with the good performance, in particular to the drug targeting carrier of an anti-tumor drug.

The invention discloses a photocurable maleic anhydride tung oil acrylic resin and a preparation method thereof. The technical scheme is as follows: the photocurable maleic anhydride tung oil acrylic resin comprises the following components: 1 mol of elacostearic acid, 2 mol of maleic anhydride (fumaric acid) and 4-5 mol of hydroxy acrylic monomer. The preparation method comprises the following steps: hydrolyzing tung oil at high pressure so as to obtain alfa-elacostearic acid, carrying out addition reaction on the maleic anhydride or the fumaric acid and a conjugated double bond of the alfa-elacostearic acid to generate a maleic/fumaric elacostearic acid, and then carrying out esterification reaction on hydroxyethyl acrylate (HEA), hydroxypropyl acrylate (HPA), hydroxyethyl methacrylate (HEMA) or hydroxypropyl methacrylate (HPMA) and the maleic/fumaric elacostearic acid to obtain various high-activity photocurable maleic anhydride tung oil penta-acrylic resins with 4-5 functionalities. The photocurable maleic anhydride tung oil acrylic resin has the characteristics of environment friendliness, no solvent, hydrolysis resistance and the like; and the paint film has excellent hardness and flexibility; as renewable resources are used for replacing a part of petrochemical products, and after the workpieces painted with the resin are discarded, the paint film is easy to degrade, and the harm of the pure chemical coating film to the environment is avoided; and after the resin is added with a photoinitiator, various photocureable coatings, printing ink and the like can be prepared.

The invention discloses a gambogic acid-galactose-HPMA (N-(2-hydroxypropyl)methacrylamide) high-molecular copolymer. The structural formula is shown as (I) in the specification. In the formula, x=5-10 mol%, y=5-10 mol%, z=80-90 mol%, Mn=2.2*10<4>, and Mw/Mn=1.45. A preparation method comprises the following steps: preparing a galactose derivative C by taking D-galactose as a preparation raw material; reacting gambogic acid oxalamide and methylacryloyl to prepare a gambogic acid derivative D; and finally, performing condensation on the galactose derivative C, the gambogic acid derivative D and HPMA to obtain the gambogic acid-galactose-HPMA high-molecular copolymer. After being used in a drug for treating a neoplastic disease, the copolymer has a targeted intelligent drug release functional and achieves a favorable inhibition effect for liver cancer, lung cancer and colon cancer.

The present invention relates to water-soluble high-molecular-weight polymer drug carriers and their conjugates with drugs, derived from dendrimers of the amidoamine and 2,2-bis(hydroxymethyl)propanoic types, the amino and hydroxy end groups of which are attached to semitelechelic copolymers of N-(2 hydroxypropyl)methacrylamide (HPMA) through biodegradable spacers. The polymer carriers and conjugates enable targeted transport notably of anticancer drugs into solid tumors in which biodegradation, the associated controlled drug release and subsequent elimination of polymer carrier from the organism are provided. The polymer carrier conjugated with a cancerostatic for use in targeted therapy of human tumors.

The invention relates to a novel graphene aerogel material and a preparation method thereof. The novel graphene aerogel material is prepared from, by weight, 40-60 parts of graphene oxide, 5-10 partsof HPMA, 100-150 parts of ammonium hydroxide, 10-20 parts of polytetrafluoroethylene, 8-10 parts of China wood oil, 6-10 parts of m-aminophenol and 50-80 parts of deionized water. The novel graphene aerogel material is easy to obtain, simple in preparation method, little in consumed time, high in mechanical strength, low in energy consumption, pollution-free, good in absorption and catalyzing effect and good in self-lubricating effect, does not easily crack or scale, and is good in dispersion effect and high in oxidation resistance, the service life of the novel graphene aerogel material is prolonged, the graphene aerogel material can be recycled and used repeatedly, the cost is lowered, and the comprehensive economic benefits are improved.

The invention discloses a novel preparing method for a scale inhibitor special for an iron-pollution-resistant film, and relates to a preparing method for a film-special scale inhibiting-dispersing agent. The scale inhibitor is prepared from 10%-30% of polyepoxysuccinic acid (PESA), 10%-30% of 2-phosphonobutane-1,2,4-tricarboxylic acid (PBTCA), 5%-15% of an allyl sulfonic acid salt copolymer (AA/AMPS), 1%-5% of styrene sulfonic acid (SS), 2%-8% of hydrolytic polymaleic anhydride (HPMA) and the balance distilled water. According to the scale inhibitor, under the condition of high-alkali, high-hardness and high-pH-value water quality and existence of iron ions, calcium carbonate scale inhibition and calcium sulfate scale inhibition reach 100%, and the scale inhibition performance for silicon dioxide scale, barium sulfate scale, strontium sulfate scale and the like is improved.

The invention provides a D-galactose/benzaldehyde nitrogen mustard/N-(2-hydroxypropyl) methacrylamide copolymer, and belongs to the field of high polymer chemistry and application. The D-galactose/benzaldehyde nitrogen mustard/N-(2-hydroxypropyl) methacrylamide copolymer is a macromolecular copolymer which has good biocompatibility and is formed in the way that D-galactose and benzaldehyde nitrogen mustard are linked to N-(2-hydroxypropyl) methacrylamide (HPMA) through covalent bonds. An experiment proves that the D-galactose/benzaldehyde nitrogen mustard/N-(2-hydroxypropyl) methacrylamide copolymer has the function of intelligently releasing drugs in a targeting manner, and has excellent inhibiting effect on a liver cancer HepG2 tumor cell; besides the macromolecular copolymer is an effective drug delivery system; therefore, the copolymer has excellent prospect as being used as an inhibitor for the HepG2 tumor cell and the like to be applied to the preparation of anti-tumor drugs.